Attached files

Global Green,  Inc.  Signs  Agreement  with Merial for  Evaluation of Salmonella
Vaccine and License Option

TALLAHASSEE,  Fla--(BUSINESS  WIRE)-- Global Green,  Inc. (GOGC) announces today
the signing of an agreement  with Merial  Ltd.,  the Animal  Health  Division of
Sanofi, to conduct an internal evaluation of Global Green's patented Salmogenics
vaccine  technology.  At the conclusion of the evaluation,  Merial has the first
option to enter into a license  agreement with Global Green for the manufacture,
distribution,  and sale of the vaccine.  Details of the evaluation agreement are
confidential.

Salmogenics is the only patented salmonella vaccine injected into the egg before
the  chick  is  hatched.  Salmogenics  significantly  reduces  the  presence  of
salmonella in the chicken.  Salmonella  is an anaerobic  bacteria that may enter
the digestive tract of humans and other mammals in  contaminated  food and cause
abdominal cramps and pain, violent vomiting and diarrhea or severe  dehydration;
it can also enter the bloodstream which may lead to death.

The aim of the Salmogenics  vaccine is to improve the immune system,  health and
welfare  of the 40  billion  broiler  chickens  in the  world  and to  provide a
healthier  source  of  protein  for  humans  in a  more  cost-effective  manner.
Salmogenics testing has demonstrated a stronger immune system against salmonella
as well as increased weight gain and reduced  mortality in poultry.  Salmogenics
could lessen the need for use of antibiotics,  an essential  benefit to both the
poultry industry and, ultimately, consumers.

Dr. Mehran Ghazvini,  DC, NMD, Chairman and CEO of Global Green,  Inc.,  stated:
"This agreement with a world leader in the animal health sector, such as Merial,
further   confirms  the  significance  of  our  patented   Salmogenics   vaccine
technology.  Our goal at Global Green,  Inc. is to produce vaccines that improve
early  immunity  in  chickens  and  other  animals,  providing  a safer and more
cost-effective food source. Global Green, Inc.'s approach to animal health is to
produce  innovative,  environmentally-safe  products and solutions which enhance
the health,  well-being  and  performance of animals."

About Merial

Merial, a Sanofi company,  is a world-leading,  innovation-driven  animal health
company  providing  a  comprehensive  range of  products  to enhance the health,
well-being and performance of a wide range of animals. With a total market share
of more than 14 percent,  Merial employs approximately 6,000 people and operates
in more than 150 countries worldwide. Its 2012 sales were $2.8 billion. For more
information,  visit  www.merial.com.  For more information  about Sanofi,  visit
http://www.sanofi.us/l/us/en/index.jsp.

About Global Green,  Inc.

Global  Green,  Inc.  is  a  green   bio-pharmaceutical   company  committed  to
identifying  technology  platforms  and  commercializing  vaccines  that contain
natural organisms that are not genetically  modified,  utilizing  pharmaceutical
standards   without   the  use  of   mercury.   For  more   information,   visit
www.globalgreeninc.com.







Forward-Looking Statement

This press release may contain  certain  forward-looking  statements  within the
meaning of Section 27A of the  Securities  Act of 1933, as amended,  and Section
21E of the Securities Exchange Act of 1934, as amended.  Investors are cautioned
that such  forward-looking  statements  involve  risks and  uncertainties  which
include,  among  others,  the  inherent  uncertainties  associated  with smaller
reporting companies  including,  without  limitation,  other risks detailed from
time to time in the Company's  periodic  reports filed with the  Securities  and
Exchange Commission.


Contact:
For Global Green, Inc.
Pam Lagano, 727-480-3082

plagano@globalgreeninc.com